BeOne Medicines Ltd. - American Depositary Shares (ONC)

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.

Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress.

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff.